Amyris
Make Good. No Compromise.®
Make Good. No Compromise.®
Amyris is a vertically integrated, synthetic biology company that creates sustainable, market-ready ingredients utilizing proprietary advanced precision fermentation technology and world-class platforms. With two decades of experience, Amyris collaborates with companies to co-create innovative ingredients at unprecedented speed and scale. This enables partners to deliver products with differentiated performance that meet sustainability and economic objectives. Its renewable and traceable ingredients are included in over 20,000 products from the world’s top brands, reaching more than 300 million consumers. It was founded in 2003 and is based in the United States. The company recently received a $50.00M Post-IPO Equity investment at 29 December 2022 from Foris Ventures. Amyris operates in the Biotechnology and Renewable Energy industries, upholding its slogan, "Make Good. No Compromise.®" For more information, please visit http://www.amyris.com.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Debt | $400.00M | - | 08 Nov 2021 | |
| Post-IPO Equity | $200.00M | - | 07 Jun 2020 | |
| Post-IPO Equity | $34.00M | 3 | Wei-Wu He, John Doerr +1 | 30 Apr 2019 |
| Grant | $25.00M | 1 | National Institutes of Health | 17 Jan 2018 |
| Post-IPO Equity | $50.00M | 2 |
|
03 Aug 2017 |
No recent news or press coverage available for Amyris.
We care about your data, and we'd love to use cookies make your experience better.
